Lazard Asset Management
CRMD icon

Lazard Asset Management’s CorMedix CRMD Stock Holding History

Lazard Asset Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$1.16M – 1915
2025
Q4 		$1.16M Buy
+100,000
New +$1.11M ﹤0.01% 1110

Other funds holding CRMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Lazard Asset Management's CRMD Position: Q1 2026 in Review

Lazard Asset Management reduced its CorMedix (CRMD) stake by 10% in Q1 2026, selling an estimated $211K and leaving 243,179 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #987.

Lazard Asset Management first reported a position in CRMD in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.16M in Q4 2025. 187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

  • Lazard Asset Management held 243,179 shares of CorMedix worth $1.65M as of Q1 2026.
  • Lazard Asset Management sold 28,511 CorMedix shares in Q1 2026, an estimated $211K.
  • CorMedix made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #987 holding.
  • Lazard Asset Management first reported a position in CorMedix in Q4 2025 and has held it in 2 quarters since.
  • Lazard Asset Management's CorMedix position peaked at $3.16M in Q4 2025.
  • 187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.